Ultragenyx Pharmaceutical Inc. (RARE): who owns it and who trades it
As of Nov 16, 2026, RARE insiders reported 28 open-market sales worth $3.8M and no purchases in the last 12 months, with 0% of the sale value made under pre-set 10b5-1 plans. The largest seller was Emil D Kakkis (CEO), with $1.2M. 4 of the 50 famous funds we follow held it at their last quarter end.
Latest filing Nov 16, 2026. From Form 4, 13F and Schedule 13D/G filings.
At a glance
Who is buying and selling Ultragenyx Pharmaceutical
From the latest filingsOverall: more buying than selling. Insiders mostly sold. Famous investors and Congress mostly bought. Funds was close to even.
Each group counts equally in the meter, by the number of buyers and sellers, not dollars. Insider sales under pre-set 10b5-1 plans are left out of it. From SEC, House and Senate filings; not advice.
Who owns RARE
311 funds and institutions reported RARE shares worth $3.7B at the end of Q2 2026. Some shares are counted by more than one filer, or lent out and counted twice, so the total can pass 100%. The largest holder is BlackRock, Inc. with 10.8%.
Funds and institutions (13F) about 100%Everyone else 0%
10 largest owners, by share of the company
Top 20 owners
| Owner | Shares | % of company | Value | Change since Q1 2026 |
|---|---|---|---|---|
| BlackRock, Inc. | 10.65M | 10.82% | $356M | +46% |
| Rtw Investments, LP | 7.80M | 7.92% | $260M | +114% |
| Vanguard Portfolio Management LLC | 6.79M | 6.89% | $227M | +26% |
| AQR Capital Management LLC | 6.56M | 6.66% | $214M | +43% |
| State Street Corp | 6.16M | 6.25% | $206M | +23% |
| Vanguard Capital Management LLC | 4.30M | 4.36% | $143M | +3% |
| Two Sigma Investments, LP | 3.62M | 3.68% | $121M | +64% |
| California State Teachers Retirement System | 3.39M | 3.44% | $101M | +3138% |
| Sands Capital Management, LLC | 3.16M | 3.21% | $105M | -2% |
| Jacobs Levy Equity Management, Inc | 2.94M | 2.98% | $98.2M | +105% |
| Frontier Capital Management Co LLC | 2.85M | 2.89% | $95.1M | +30% |
| Geode Capital Management, LLC | 2.58M | 2.62% | $86.1M | +39% |
| Bellevue Group AG | 1.98M | 2.01% | $66.2M | -17% |
| D. E. Shaw & Co., Inc. | 1.73M | 1.76% | $57.8M | +37% |
| Sofinnova Investments, Inc. | 1.72M | 1.74% | $57.3M | -45% |
| Adage Capital Partners Gp, L.l.c. | 1.58M | 1.60% | $52.8M | +229% |
| GW&K Investment Management, LLC | 1.48M | 1.50% | $49.5M | -8% |
| Mpm Bioimpact LLC | 1.42M | 1.44% | $47.4M | – |
| T. Rowe Price Associates | 1.36M | 1.38% | $45.3M | +69% |
| Morgan Stanley | 1.32M | 1.35% | $44.2M | -12% |
From the SEC 13F data sets: every fund manager with over $100M must report its US stock holdings every 3 months, up to 45 days after the quarter ends. Owners are shown as they file, so one group (for example Vanguard) can appear under several names. Individuals, most insiders and smaller funds do not file 13F reports.
Insider trades
In the last 12 months, RARE insiders reported $0 of open-market purchases and $3.8M of sales. 0% of the sale value was under a 10b5-1 plan, a schedule set up in advance.
Purchases and sales by month
Latest trades
| Date | Insider | Role | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|---|
| Oct 15, 2026 | Howard Horn | CFO | Sale | 7,066 | $15.27 | $108K | Form 4 |
| Sep 15, 2026 | Theodore Alan Huizenga | Vice president | Sale | 1,283 | $13.57 | $17.4K | Form 4 |
| Sep 3, 2026 | Theodore Alan Huizenga | Vice president | Sale | 161 | $13.99 | $2.3K | Form 4 |
| Aug 3, 2026 | Karah Herdman Parschauer | Vice president | Sale | 1,900 | $24.92 | $47.3K | Form 4 |
| Aug 3, 2026 | Howard Horn | CFO | Sale | 4,696 | $24.92 | $117K | Form 4 |
| Jul 1, 2026 | Howard Horn | CFO | Sale | 4,698 | $33.13 | $156K | Form 4 |
| Jun 15, 2026 | Corazon (Corsee) D. Sanders | Director | Sale | 2,000 | $25.05 | $50.1K | Form 4 |
| Jun 15, 2026 | Karah Herdman Parschauer | Vice president | Sale | 1,899 | $24.62 | $46.8K | Form 4 |
| Jun 1, 2026 | Howard Horn | CFO | Sale | 4,653 | $23.77 | $111K | Form 4 |
| May 18, 2026 | Shehnaaz Suliman | Director | Sale | 5,740 | $25.12 | $144K | Form 4 |
| May 5, 2026 | Eric Crombez | Vice president | Sale | 344 | $24.96 | $8.6K | Form 4 |
| May 1, 2026 | Howard Horn | CFO | Sale | 4,683 | $24.90 | $117K | Form 4 |
| Apr 1, 2026 | Howard Horn | CFO | Sale | 4,683 | $20.97 | $98.2K | Form 4 |
| Mar 10, 2026 | Karah Herdman Parschauer | Vice president | Sale | 3,508 | $22.67 | $79.5K | Form 4 |
| Mar 6, 2026 | Karah Herdman Parschauer | Vice president | Sale | 6,018 | $21.40 | $129K | Form 4 |
| Mar 3, 2026 | Howard Horn | CFO | Sale | 1,635 | $22.40 | $36.6K | Form 4 |
| Mar 2, 2026 | John Richard Pinion | See Remarks | Sale | 10,029 | $22.80 | $229K | Form 4 |
| Mar 2, 2026 | Erik Harris | Vice president | Sale | 10,539 | $22.80 | $240K | Form 4 |
| Mar 2, 2026 | Emil D Kakkis | CEO | Sale | 54,404 | $22.80 | $1.2M | Form 4 |
| Mar 2, 2026 | Karah Herdman Parschauer | Vice president | Sale | 8,135 | $22.80 | $185K | Form 4 |
| Mar 2, 2026 | Theodore Alan Huizenga | Vice president | Sale | 1,632 | $22.80 | $37.2K | Form 4 |
| Mar 2, 2026 | Howard Horn | CFO | Sale | 5,290 | $22.80 | $121K | Form 4 |
| Mar 2, 2026 | Howard Horn | CFO | Sale | 3,119 | $22.54 | $70.3K | Form 4 |
| Mar 2, 2026 | Eric Crombez | Vice president | Sale | 7,029 | $22.80 | $160K | Form 4 |
| Feb 2, 2026 | Howard Horn | CFO | Sale | 3,061 | $23.56 | $72.1K | Form 4 |
| Jan 2, 2026 | Howard Horn | CFO | Sale | 3,150 | $22.84 | $71.9K | Form 4 |
| Dec 29, 2025 | Theodore Alan Huizenga | Vice president | Sale | 85 | $34.38 | $2.9K | Form 4 |
| Dec 10, 2025 | Howard Horn | CFO | Sale | 3,081 | $36.38 | $112K | Form 4 |
Insiders by value traded
| Insider | Role | Bought | Sold | Last trade |
|---|---|---|---|---|
| Emil D Kakkis | President & CEO, Director | – | $1.2M | Mar 2, 2026 |
| Howard Horn | Chief Financial Officer | – | $1.2M | Oct 15, 2026 |
| Karah Herdman Parschauer | EVP and Chief Legal Officer | – | $488K | Aug 3, 2026 |
| Erik Harris | EVP & Chief Commercial Officer | – | $240K | Mar 2, 2026 |
| John Richard Pinion | See Remarks | – | $229K | Mar 2, 2026 |
| Eric Crombez | EVP and Chief Medical Officer | – | $169K | May 5, 2026 |
| Shehnaaz Suliman | Director | – | $144K | May 18, 2026 |
| Theodore Alan Huizenga | SVP, Chief Accounting Officer | – | $59.8K | Sep 15, 2026 |
| Corazon (Corsee) D. Sanders | Director | – | $50.1K | Jun 15, 2026 |
What this data shows, and what it doesn't
- Shows: open-market purchases and sales by officers, directors and 10%+ owners, reported on Form 4 within two business days of the trade.
- Leaves out: stock awards, option exercises, shares withheld for tax and gifts. These are not trades at a market price chosen by the insider.
- "plan" marks a sale made under a Rule 10b5-1 plan, a schedule set up in advance.
- Fund holders come from 13F reports, a snapshot at quarter end filed up to 45 days later.
- Filings are self-reported and can be amended. Each trade links to its original filing. Methodology
RARE short interest
Very high short interest. 23.2% of RARE shares are sold short: about 1 share in 4. Over the last 12 reports the number of shares short went up 69%.
As a rough guide, under 5% is low, 5–10% is moderate, 10–20% is high and over 20% is very high.
As of Oct 30, 2026, 23.62M RARE shares were sold short, 23.2% of the shares outstanding, up 17.3% from the report before. At the average daily volume of 2.86M shares, buying them all back would take about 8.3 trading days (days to cover).
Shares short, % of all shares
Days to cover
Every report
| Settlement date | Shares short | % of shares | Change | Avg daily volume | Days to cover |
|---|---|---|---|---|---|
| Oct 30, 2026 | 23.62M | 23.18% | +17% | 2.86M | 8.3 |
| Oct 15, 2026 | 20.15M | 20.43% | -1% | 3.89M | 5.2 |
| Sep 30, 2026 | 20.35M | 20.64% | +23% | 6.50M | 3.1 |
| Sep 15, 2026 | 16.57M | 16.81% | -3% | 7.46M | 2.2 |
| Aug 31, 2026 | 17.14M | 17.39% | +8% | 2.14M | 8.0 |
| Aug 14, 2026 | 15.89M | 16.12% | +6% | 2.04M | 7.8 |
| Jul 31, 2026 | 14.96M | 15.18% | +11% | 1.81M | 8.3 |
| Jul 15, 2026 | 13.44M | 13.64% | -17% | 1.94M | 6.9 |
| Jun 30, 2026 | 16.22M | 16.47% | +13% | 4.50M | 3.6 |
| Jun 15, 2026 | 14.31M | 14.53% | -3% | 1.62M | 8.8 |
| May 29, 2026 | 14.70M | 14.93% | +5% | 1.50M | 9.8 |
| May 15, 2026 | 13.98M | 14.19% | +2% | 1.70M | 8.2 |
Short sellers borrow shares and sell them, hoping to buy them back for less. A high number means many such bets are open. It does not say where the price will go. Source: FINRA equity short interest, reported by brokers twice a month (positions on the 15th and the last business day) and published about 7 business days later. % of shares uses the share count on the company's latest SEC filing. What short interest means · Most shorted stocks
Members of Congress who traded RARE
Since Nov 17, 2024, 1 member of Congress reported 5 purchases and 0 sales of RARE. The latest was a purchase by Gilbert Ray Cisneros, Jr. on Sep 29, 2026, reported Oct 12, 2026.
Purchases 5Sales 0
Reported trades
| Trade date | Member | Type | Amount | Owner | Reported | Source |
|---|---|---|---|---|---|---|
| Sep 29, 2026 | Gilbert Ray Cisneros, Jr. (D-CA) | Purchase | $1K–$15K | Self | Oct 12, 2026 | Report |
| Mar 3, 2026 | Gilbert Ray Cisneros, Jr. (D-CA) | Purchase | $1K–$15K | Self | Apr 7, 2026 | Report |
| Feb 18, 2026 | Gilbert Ray Cisneros, Jr. (D-CA) | Purchase | $1K–$15K | Self | Mar 9, 2026 | Report |
| Aug 8, 2025 | Gilbert Ray Cisneros, Jr. (D-CA) | Purchase | $1K–$15K | Self | Sep 12, 2025 | Report |
| Jul 15, 2025 | Gilbert Ray Cisneros, Jr. (D-CA) | Purchase | $1K–$15K | Self | Aug 14, 2025 | Report |
Source: Periodic Transaction Reports filed with the Clerk of the House and the Secretary of the Senate under the STOCK Act. Members report each trade within 45 days, as a dollar range, not an exact amount. Trades by a spouse or dependent child are included and marked. Paper filings (scanned images) are not included, and Senate reports are shown for current senators only. Links to Senate reports open the Senate’s own site, which shows its terms first and can only be reached from the United States. How these reports work
Ultragenyx Pharmaceutical company events
Ultragenyx Pharmaceutical filed 21 reports on Form 8-K in the last 12 months, 2 of them about an important change (leadership, job cuts). The latest was on Nov 3, 2026.
- Nov 3, 2026DealUltragenyx Pharmaceutical Inc. completed the previously disclosed sale of its Rare Pediatric Disease Priority Review Voucher to the buyer. Filing
- Oct 19, 2026AnnouncementUltragenyx Pharmaceutical Inc. and Baylor Research Institute entered into a settlement agreement with Navinta LLC resolving patent litigation related to patents covering the Company’s DOJOLVI® (triheptanoin) oral liquid. Filing
- Oct 14, 2026AgreementUltragenyx Pharmaceutical Inc. entered into an asset purchase agreement, pursuant to which the Company agreed to sell a Rare Pediatric Disease Priority Review Voucher to the buyer. Filing
- Oct 7, 2026AgreementUltragenyx Pharmaceutical Inc. entered into an asset purchase agreement, pursuant to which the Company agreed to sell a Rare Pediatric Disease Priority Review Voucher to the buyer. Filing
- Sep 17, 2026AnnouncementUltragenyx Pharmaceutical Inc. announced that the U.S. Food and Drug Administration granted standard full approval of FAYUVI™ (rebisufligene etisparvovec-hopf), also known as UX111, for the treatment of pediatric patients with mucopolysaccharidosis type IIIA (MPS IIIA, Sanfilippo syndrome Type A). Filing
- Sep 2, 2026AnnouncementUltragenyx Pharmaceutical Inc. announced results from the Phase 3 Aspire study for apazunersen (GTX-102) in Angelman syndrome. Filing
- Aug 19, 2026AnnouncementUltragenyx Pharmaceutical Inc. announced the U.S. Food and Drug Administration granted accelerated approval for GENGLYCOS™ (pariglasgene brecaparvovec-opnr), also known as DTX401, in adult and pediatric patients eight years and older with glycogen storage disease type Ia (GSDIa). Filing
- Aug 11, 2026AnnouncementUltragenyx Pharmaceutical Inc. and Baylor Research Institute entered into a settlement agreement with Esjay Pharma Private Limited and Esjay Pharma LLC (collectively, “Esjay”) resolving patent litigation related to the Company’s DOJOLVI® (triheptanoin) oral liquid. Filing
- Aug 4, 2026ResultsReleased financial results. Filing
- May 18, 2026LeadershipAs reported below, at its Annual Meeting of Stockholders on May 14, 2026, the stockholders of Ultragenyx Pharmaceutical Inc. approved the Third Amended and Restated 2023 Incentive Plan. Filing
- May 5, 2026ResultsReleased financial results. Filing
- Apr 2, 2026AnnouncementUltragenyx Pharmaceutical Inc. issued a press release announcing that the U.S. Food and Drug Administration has accepted for review the Company’s resubmitted Biologics License Application seeking accelerated approval for UX111 (rebisufligene etisparvovec) AAV9 gene therapy as a treatment for… Filing
- Mar 30, 2026AnnouncementUltragenyx Pharmaceutical Inc. issued a press release announcing that the U.S. Food and Drug Administration has cleared the Investigational New Drug application for UX016, an investigational small molecule prodrug of sialic acid being evaluated as a substrate replacement therapy for GNE myopathy. Filing
- Mar 12, 2026AnnouncementUltragenyx Pharmaceutical Inc. issued a press release announcing positive results from its Phase 3 Enh3ance study of DTX301, an investigational AAV8 gene therapy for the treatment of ornithine transcarbamylase deficiency. Filing
- Feb 23, 2026AnnouncementUltragenyx Pharmaceutical Inc. issued a press release announcing that the U.S. Food and Drug Administration has accepted for review the Biologics License Application seeking approval of DTX401 AAV gene therapy (pariglasgene brecaparvovec) for the treatment of Glycogen Storage Disease Type Ia (GSDIa). Filing
- Feb 12, 2026Job cutsAnnounced job cuts or other exit costs. Filing
- Feb 3, 2026AnnouncementUltragenyx Pharmaceutical Inc. issued a press release announcing new long‑term data from clinical studies evaluating UX111 (rebisufligene etisparvovec), an investigational AAV9 gene therapy for Sanfilippo syndrome type A (MPS IIIA), a fatal neurodegenerative lysosomal storage disorder. Filing
- Jan 30, 2026AnnouncementUltragenyx Pharmaceutical Inc. issued a press release announcing that that it has resubmitted its Biologics License Application seeking accelerated approval for UX111 (rebisufligene etisparvovec) AAV9 gene therapy as a treatment for patients with Sanfilippo syndrome type A (MPS IIIA) to the U.S.… Filing
- Jan 12, 2026ResultsReleased financial results. Filing
- Dec 30, 2025AnnouncementUltragenyx Pharmaceutical Inc. issued a press release announcing that that it has completed the rolling submission of its Biologics License Application to the U.S. Food and Drug Administration seeking approval for DTX401 AAV gene therapy (pariglasgene brecaparvovec) as a treatment for Glycogen… Filing
- Dec 29, 2025AnnouncementUltragenyx Pharmaceutical Inc. announced results from the Phase 3 Orbit and Cosmic studies for setrusumab (UX143) in Osteogenesis Imperfecta. Filing
From 8-K reports, which a company must file within 4 business days of an important event. Where a report is about a change such as a new CEO, the sentence is the first one from the report itself, shortened. Each row links to the original filing. Company events this week
Ultragenyx Pharmaceutical financials
Famous investors that hold RARE
4 of the 50 well-known investors we track reported holding RARE in their latest 13F filing. The largest position is Israel Englander's, worth $22.8M.
Position size
All holders
| Fund | Quarter | Shares | Value | Of portfolio | Change |
|---|---|---|---|---|---|
| Israel Englander · Millennium Management | Q3 2026 | 1.52M | $22.8M | 0.0% | +100% |
| Steve Cohen · Point72 Asset Management | Q3 2026 | 844,410 | $12.7M | 0.0% | New |
| Ken Griffin · Citadel Advisors | Q3 2026 | 356,670 | $5.4M | 0.0% | +69% |
| Ray Dalio · Bridgewater Associates | Q3 2026 | 57,052 | $857K | 0.0% | New |
From 13F reports: a snapshot at quarter end, filed up to 45 days later. Change compares with the quarter before.
5%+ stakes filed in the last 120 days
Anyone who owns more than 5% of a company must report it on Schedule 13D or 13G. 8 filings named RARE in the last 120 days.
| Filed | Holder | Form | Stake |
|---|---|---|---|
| Nov 13, 2026 | AQR Capital Management, LLC | 13G/A | 0.6% |
| Nov 13, 2026 | AQR Capital Management, LLC | 13G/A | 0.6% |
| Nov 10, 2026 | STATE STREET CORPORATION | 13G | 7.6% |
| Nov 10, 2026 | STATE STREET CORPORATION | 13G | 7.6% |
| Oct 30, 2026 | Vanguard Portfolio Management | 13G/A | 8.6% |
| Oct 30, 2026 | Vanguard Portfolio Management | 13G/A | 8.6% |
| Oct 20, 2026 | Madison Avenue International LP | 13G | 6.4% |
| Oct 20, 2026 | Madison Avenue International LP | 13G | 6.4% |
Questions about Ultragenyx Pharmaceutical Inc. (RARE) stock
Who owns the most RARE stock?
The largest reported owner of Ultragenyx Pharmaceutical Inc. (RARE) is BlackRock, Inc., with 10.8% of the company. In total, 311 funds and institutions reported holding RARE at the end of Q2 2026, together about 100% of the shares. See the largest owners.
Are RARE insiders buying or selling?
In the last 12 months, RARE insiders reported no open-market purchases and 28 sales worth $3.8M. The latest trade was on Oct 15, 2026. See every trade.
What is the short interest in RARE?
As of Oct 30, 2026, 23.62M RARE shares were sold short, 23.2% of the shares outstanding, up 17.3% from the report before. At the average daily volume of 2.86M shares, buying them all back would take about 8.3 trading days (days to cover). See the history.
Have members of Congress traded RARE?
Yes. 1 member of Congress reported 5 purchases and 0 sales of RARE since Nov 17, 2024. The latest was reported on Oct 12, 2026. See the trades.
Which famous investors hold RARE?
4 of the 50 well-known investors we track reported RARE in their latest 13F filing, including Israel Englander, Steve Cohen, Ken Griffin. The largest position is worth $22.8M. See all holders.
Source: SEC Form 4 (insiders, filed within 2 business days), 13F (funds, up to 45 days after quarter end) and Schedule 13D/13G filings. Only open-market purchases (code P) and sales (code S) are shown. Data only, not investment advice. How we collect it.